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Reading the Future?: Legal and Ethical Challenges of Predictive
Genetic Testing is a new book updating the work of a group of legal
scholars who, in 2001, provided advice to the Ontario Advisory
Committee on New Predictive Genetic Technologies. Together with
Lisa Austin and Bita Amani, the authors made recommendations to the
Advisory Committee on the management of a range of legal and ethical
issues in genetic testing.
Clinical geneticist Doctor Anne. Summers chaired the Advisory
Committee which conducted its work from April 2000 through
November 2001. The province of Ontario was at that time leading the
Canadian response to a potential deluge (described by some as a
"tsunami") of developments in genetic testing. These technological
developments were rendered even more vexing by the way in which they
were being marketed. Myriad Genetics, a Utah-based biotechnology
'[Reading the Future].
2 Associate Professor, Department of Health Policy, Management and Evaluation,
University of Toronto.
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company, was forging ahead in its effort to impose exclusive or
restrictive licences in the international delivery of genetic tests. This
business model was especially egregious because Myriad claimed
exclusive rights to the genes for hereditary breast and ovarian cancer
(BRCA1 and BRCA2) and sought to exercise this claim beyond its
successful commercial base in the United States to Europe and Canada,
where health care delivery was less commercialized.
The Advisory Committee was announced alongside the
introduction of provincially funded *services for the delivery of genetic
testing for the hereditary cancer syndromes, services that defied the
claims of Myriad Genetics. The Committee rushed to deliver its report,3
just prior to the release of the Ministry of Health and Long-Term Care's
report4 to the Premiers' Conference of January 2002, which advanced a
series of recommendations for action by government. The Ministry's
report is one of several that have fostered an international dialogue
about genetic testing in health care and emphasized the importance of
finding a balance between support for intellectual property rights and
innovation on the one hand, and support of sustainable and accessible
research practices and health systems on the other.
This fraught policy context explains the book's origins and much
about its content. The book starts from the premise that legislative and
regulatory intervention is needed, and proposes to elaborate on systems
of deliberation, oversight, and control to avert potential harms. As an
analysis of what might go amiss if predictive genetic tests were to
proliferate, and what might be done if governments were forced to act,
this book provides a useful overview grounded in the Canadian-and
especially Ontarian-context.
Framed by a brief introduction and conclusion, the book is
delivered as a series of eight sections, each of which addresses an area of
concern and lists recommendations to mitigate potential harms. The
scope of analysis is broad: the authors are concerned primarily with the
medical uses of genetic testing, but also address non-clinical uses such as
' Genetic Services in Ontarior Mapping the Future (Toronto: Queen's Printer for Ontario,
2001) online: Ontario Ministry of Health and Long- Term Care <http://www.health.gov.on.ca/
english/public/pub/ministry-reports/geneticsrep01/genetic-report.pdf >
4 Genetics, Testing & Gene Patenting.- Charting New Territory in Healthcare (Toronto:
Queen's Printer for Ontario, 2002) online: Ontario Ministry of Health and Long-Term Care
<http:/iwww.health.gov.on.ca/english/public/pub/ministry-reports/ geneticsrep02/reporte.pdf >.
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genetic testing in the workplace and impacts of predictive testing on
adoption, certain aspects of research such as genetic databanks, and the
intellectual property environment that supports commercial
development and delivery. The analysis is grounded in a review of
international policy statements, commission and committee reports,
consideration of relevant Canadian legislation (focused primarily but
not exclusively on Ontario), and legal scholarship.
Each section of the book can be considered independently,
highlighting the value of the text as an educational resource. Students
might be directed to sections of the text, or review it section by section
as they are introduced to the various ways in which legal concerns and
institutions intersect with developments in health technology.
The first substantive section of the book considers genetic
discrimination and stigmatization in diverse contexts such as
employment, insurance, financial services, adoption, education, and
health services. The authors recommend legislative changes to bolster
the protections provided by human rights codes as well as legislative and
regulatory oversight mechanisms to monitor and control the use of
genetic tests outside health care contexts. The second section provides a
useful overview of the governance of research involving human subjects
in Canada. Canada has, as the authors point out, a system of guidelines
rather than a set of formal statutes or regulations governing the use of
predictive genetic testing. While the authors recommend more
regulatory oversight, the relevance of these generic.issues in research
governance as applied to the context of genetics is suggested only in
closing, and without much conviction. Further, recent debates in
research ethics and regulation that have specific relevance for
genetics-such as the potential obligation to communicate genetic
research results-are not discussed.
A brief section recommending "equitable access" to [beneficial]
genetic services5 is then followed by an analysis of gene patenting by
Lisa Austin and Bita Amani. This section provides a helpful
introduction to the range of issues in both domestic and international
law that bear on patents on biotechnological inventions in general, and
patents on genes in particular. However, the section was drafted in 2003
and requires updating. A page of dense text at the end of the section
' Supra note 1 at 99.
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providing an update as to recent developments does not address this
problem.
A discussion of commercialization and the direct marketing of
genetic tests follows the section on intellectual property. Highlighting
the jurisdictional challenges of commercial genetic testing, the authors
recommend discussions between provincial and federal governments
and across international borders in order to effectively regulate this
area. Turning next to clinical issues, the authors offer a helpful review of
the role of genetic counsellors in the delivery of genetic services and
recommend the introduction of professional regulation for this group of
clinicians.
The penultimate section considers some of the legal issues
arising in the clinical delivery of genetic testing services, including issues
of consent, disclosure, privacy and confidentiality, and the specific issues
that arise in genetic testing of minors, incapable persons, and those with
reduced capacity. This section briefly addresses a host of highly complex
issues including consent for multiplex testing, the web of duties that
arise from the familial nature of genetic testing, the capacity for genetic
testing to provide unexpected results, the duties of confidentiality and
disclosure, and rights of patients not to know. The final section
examines the storage of genetic material and information, with
consideration of personal, clinical, and research uses. Legislation is
recommended to protect the privacy of stored genetic information, and
to establish standards for collection, access, duration of retention, and
disposal and follow-up for stored samples.
Throughout the book, the authors are attentive to legal and
policy debates. These include how a "right not to know" can be upheld
given the familial nature of genetic information that may breach one
family member's desire to remain ignorant, and whether clinicians are
obligated to communicate unexpected findings to patients, especially
when these findings do not have clinical relevance. Yet the ethical
debates that surround these legal and policy issues are considered to a
lesser degree. What is the ethical underpinning of any 'right not to
know'? Does such a right, if it exists, derive from the right to autonomy,
as is typically and narrowly argued, or is it a more expansive right that
derives from a right to privacy, as Graeme Laurie has argued?6 Can
6 See Graeme T. Laurie, "In Defence of Ignorance: Genetic Information and the Right Not
to Know" (1999) 6 European Journal of Health Law 119 and "Protecting and Promoting Privacy in
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advance warning and informed consent protect against the potential
harms of the unintended findings of genetic testing (e.g., misattributed
paternity), or does advance notification fail to resolve the issue, as
argued by Erica Lucast? 7 While the omission of these debates is
understandable-a single tome can only do so much-it limits the
appeal of the book for more advanced readers. Further, I wonder
whether this omission might be even more instrumental by limiting
consideration of the legal remedies that might be required. If a right not
to know resides in a right to privacy, the right might be observed even
without express consent, with the burden placed on those who would
disclose knowledge of no clear clinical significance to justify the
infringement. Similarly, if advance warning and informed consent
cannot avert the harms of unintended knowledge, how can these harms
be mitigated, and what might be required to avoid the generation of
unintended results?
The book offers a sustained analysis of the breadth of legal and
policy issues that might arise from developments in predictive genetic
testing. It also reads as a sustained call for intensive legislative,
regulatory, and policy development in the area of predictive genetic
testing. And this is where policy analysts (of whom the reviewer is one)
part company with legal scholars. The conflicted policy context that
birthed this book is no longer with us, and in my view, the justification
for intensive governmental action is no longer obvious. In Ontario, the
permanent Advisory Committee that was recommended by Anne
Summer's Committee, and established shortly thereafter, has been
allowed to die a slow death of neglect: Orders-in-Council are still
standing, but no meetings have been called. Claims of a "tsunami" of
genetic tests identifying an array of highly significant clinical risks have
gone silent. Finally, the Byzantine business model promoted by Myriad
Genetics has been chastened by widespread opprobrium.
When Summer's Committee was convened, claims about
expansive growth in predictive capacity using genetic information were
circulating widely. Auspicious individuals like the Director of the US
National Human Genome Research Institute, Francis S. Collins, offered
an Uncertain World: Further Defences of Ignorance and the Right Not to Know" (2000) 7
European Journal of Health Law 185..
' See Erica K. Lucast, "Informed Consent and the Misattributed Paternity Problem in
Genetic Counseling" (2007) 21 Bioethics 41.
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clinical scenarios, such as the story of "John" who took a battery of
genetic tests in 2010 leading to personalized pharmacologic treatments,
intensive surveillance, and profound behaviour change.8 Thus, the
authors are specifically concerned with predictive genetic testing,
arguing that, "genetic information is most often risk information, used
for predicting future health status rather than for direct diagnostic
purposes." 9 In my view, this latter claim is in error as most clinical uses
of genetic testing are diagnostic. Clear differences between predictive
and diagnostic uses of genetic testing are hard to sustain. Many
individuals who use "predictive" tests to identify hereditary risks for
BRCA1/2 already have cancer; for them, results are both diagnostic and
predictive of future risks (e.g., of secondary cancers), and have both
health and reproductive implications.1"
More importantly, the book originated in a call to consider
remedies when the potential harms of predictive genetic testing were
believed to be both likely and serious. Thus, the authors provide only a
brief justification for the special attention given to genetic testing,
suggesting that genetic data is somewhat unique, and that the contexts
for the circulation of genetic testing intensify the need for oversight.
They provide no clear rationale for the protective measures that they
suggest. Is there a real and pressing need for legislation to curb genetic
discrimination? Does commercial genetic testing require specific
oversight or regulation that is different in kind or focus from other
regulatory initiatives? Is additional legislation required to protect the
privacy of genetic information? Finally, are the measures suggested
proportional to the harms to be averted?
In the spring of 2000, the authors were given an impossible task:
to provide a comprehensive overview of the legal and ethical challenges
that might arise from then-anticipated developments in predictive
genetic testing. The authors did a commendable job in the short time
available by providing a thorough analysis of many of these issues to be
included in the final report. They then continued their work, seeking to
complete the assigned task. The finished work represents a
commendable effort to scope out and consider the range of issues
'Francis S. Collins, "Shattuck Lecture: Medical and Societal Consequences of the Human
Genome Project" (1999) 341 New England Journal of Medicine 28.
9 Supra note 1 at 4.
" Supra note 1 at 167.
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arising from developments in predictive genetic testing, and an
enormous amount of valuable information was compiled. Had the
authors left the manuscript in that form, I would have no quibble. But
they chose to also advance policy recommendations. In 2001, the
premise that strong action was needed was widely accepted. But the
policy context has changed: 2007 is a fair distance from 2001.

